Reunion Neuroscience Inc. - REUN STOCK NEWS

Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) has announced that its Phase 1 study results for RE104, a novel psychedelic compound aimed at treating postpartum depression (PPD), will be presented at the 2023 American Society of Clinical Psychopharmacology Annual Meeting in Miami from May 30 to June 2. Key findings indicate that RE104 is safe, well-tolerated, and exhibits significant pharmacodynamic effects, with a shorter duration compared to psilocybin. With PPD impacting 1 in 8 mothers, Reunion aims to provide rapid symptom relief through RE104, which has completed phase 1 with 48 subjects.

Reunion Neuroscience Inc. (NASDAQ: REUN) has filed a lawsuit against Mindset Pharma Inc. in the U.S. District Court for New Jersey, claiming that Mindset copied Reunion's RE104 compound and misrepresented it in a patent application for U.S. Patent No. 11,591,353. Reunion seeks to add its Chief Scientific Officer, Dr. Nathan Bryson, as an inventor on this patent. The company is committed to protecting its intellectual property while developing its lead asset, RE104, for treating postpartum depression. RE104 is backed by U.S. Patent No. 11,292,765, which is valid until June 30, 2041.

Reunion Neuroscience, a clinical-stage biopharmaceutical firm focusing on mental health, will present at the Oppenheimer Annual Healthcare Conference on March 14, 2023, at 4:00 PM ET. The presentation will highlight the company's lead asset, RE104, a novel serotonergic psychedelic compound aimed at treating postpartum depression, with significant patent protection until June 2041. The event will be available via webcast and can be accessed on their website, where the presentation will be archived. Reunion is also developing the RE200 series to enhance receptor selectivity for additional therapeutic uses.

Reunion Neuroscience Inc. (NASDAQ: REUN) reported promising Phase 1 interim data for RE104, demonstrating strong safety and tolerability, with no serious adverse events. As of December 31, 2022, the company held CAD $32.4 million in cash. CEO Greg Mayes emphasized the transformative nature of the quarter and the encouraging pharmacokinetic results of RE104, a treatment for postpartum depression (PPD). In 2023, Reunion plans to share data with the FDA and initiate a Phase 2 study. The company is expanding its leadership team, recently appointing Dr. Robert Alexander as Chief Medical Officer. However, Reunion reported a net loss from continuing operations of $12.5 million for Q3 2023.

Reunion Neuroscience Inc. (NASDAQ: REUN) announced plans to release its business update and financial results for Q3 fiscal 2023, ending December 31, 2022, on February 14, 2023, before market open. A conference call will follow at 8:30 a.m. ET, discussing these results. Reunion focuses on developing innovative treatments for mental health conditions, particularly RE104, a new serotonergic psychedelic compound targeting postpartum depression. This compound is protected under US Patent No. 11,292,765, effective until June 30, 2041. Investors can access the call through the Reunion investor relations website.

Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) announced the appointment of Dr. Robert Alexander as Chief Medical Officer, effective immediately. Dr. Alexander, a seasoned biotech veteran with extensive leadership experience at Takeda, Pfizer, AstraZeneca, GSK, and Merck, will oversee the advancement of RE104, the company’s lead asset in its Phase 2 clinical study for postpartum depression. The firm highlights that RE104 is a unique 4-OH-DiPT psychedelic compound with a strong patent position extending to 2041, reinforcing its competitive advantage. The management anticipates that Dr. Alexander’s expertise will be instrumental in navigating the complexities of clinical trials and enhancing treatment options for patients.

Reunion Neuroscience has released positive interim findings from its Phase 1 clinical trial of RE104, a serotonergic psychedelic compound for treating postpartum depression. The trial, involving 32 healthy volunteers, showed strong safety with no severe adverse events. Notably, participants experienced a significant reduction in psychedelic duration (3-4 hours for RE104 vs. 6-8 hours for psilocybin) and a high incidence of "complete mystical experience". Reunion plans to engage with the FDA for Phase 2 development.

Reunion Neuroscience Inc. (NASDAQ: REUN) is advancing its lead psychedelic compound, RE104, through clinical development, specifically targeting postpartum depression (PPD). The company plans to report interim Phase 1 analysis results in Q1 2023, focusing on safety, tolerability, and dosing levels. They aim to initiate a Phase 2 study for PPD treatment in late 2023. With PPD affecting 1 in 8 mothers and only one FDA-approved treatment available, RE104 could offer a fast-acting, durable solution.

Reunion Neuroscience Inc. (NASDAQ: REUN) has announced its participation in several investor conferences in December 2022, focusing on mental health innovations. Key events include:

• Stifel Canada's The Future of Healthcare Conference on December 7, 2022, at 2:00 p.m. ET.
• Canaccord Genuity Symposium on December 13, 2022, at 10:00 a.m. ET.
• KCSA Mental Health Conference on December 15, 2022, at 10:00 a.m. ET.

Reunion's lead asset, RE104, a patented compound for treating postpartum depression, has received patent protection until 2041.